GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celcuity Inc (NAS:CELC) » Definitions » Price-to-Tangible-Book

Celcuity (Celcuity) Price-to-Tangible-Book : 3.60 (As of May. 26, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Celcuity Price-to-Tangible-Book?

As of today (2024-05-26), Celcuity's share price is $15.64. Celcuity's Tangible Book per Share of Mar. 2024 for the quarter that ended in Mar. 2024 was $4.35. Hence, Celcuity's Price to Tangible Book Ratio of today is 3.60.

The historical rank and industry rank for Celcuity's Price-to-Tangible-Book or its related term are showing as below:

CELC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.83   Med: 4.49   Max: 11.41
Current: 3.6

During the past 9 years, Celcuity's highest Price to Tangible Book Ratio was 11.41. The lowest was 1.83. And the median was 4.49.

CELC's Price-to-Tangible-Book is ranked worse than
60.61% of 1221 companies
in the Biotechnology industry
Industry Median: 2.79 vs CELC: 3.60

A closely related ratio is called PB Ratio. As of today, Celcuity's share price is $15.64. Celcuity's Book Value per Sharefor the quarter that ended in Mar. 2024 was $4.35. Hence, Celcuity's P/B Ratio of today is 3.60.


Celcuity Price-to-Tangible-Book Historical Data

The historical data trend for Celcuity's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celcuity Price-to-Tangible-Book Chart

Celcuity Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only 5.65 8.06 2.86 2.27 2.66

Celcuity Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.83 2.20 2.20 2.66 4.97

Competitive Comparison of Celcuity's Price-to-Tangible-Book

For the Biotechnology subindustry, Celcuity's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celcuity's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celcuity's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Celcuity's Price-to-Tangible-Book falls into.



Celcuity Price-to-Tangible-Book Calculation

Celcuity's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Mar. 2024 )
=15.64/4.346
=3.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


Celcuity Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Celcuity's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


Celcuity (Celcuity) Business Description

Traded in Other Exchanges
N/A
Address
16305 36th Avenue North, Suite 100, Minneapolis, MN, USA, 55446
Celcuity Inc is a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications. The company's therapeutic candidate is gedatolisib, a potent, well-tolerated, small molecule dual inhibitor, administered intravenously, that selectively targets all Class I isoforms of PI3K and the mammalian target of rapamycin (mTOR).
Executives
Richard E Buller director C/O CELCUITY INC., 16305 36TH AVE. N., #100, MINNEAPOLIS MN 55446
David Dalvey director C/O BLUE ROCK ADVISORS, INC., 80 SOUTH EIGHTH STREET SUITE 3915, MINNEAPOLIS MN 55402
Leo Furcht director C/O CELCUITY, 16305 36TH AVENUE N., #100, MINNEAPOLIS MN 55445
Brian F Sullivan director, 10 percent owner, officer: Chief Executive Officer 16305 36TH AVENUE N, MINNEAPOLIS MN 55446
Polly A. Murphy director C/O ATEA PHARMACEUTICALS, INC., 125 SUMMER STREET, BOSTON MA 02110
Richard Nigon director CEDAR POINT CAPITAL, 150 SOUTH 5TH STREET, MINNEAPOLIS MN 55402
Lance G. Laing director, 10 percent owner, officer: Chief Science Officer, VP C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Vicky Hahne officer: Chief Financial Officer C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446
Maureen Therese Cronin director C/O CELCUITY, 16305 36TH AVENUE N., #450, MINNEAPOLIS MN 55446